Prof Marija Krstic-Demonacos' Outputs (38)

Insight into glucocorticoid receptor signalling through interactome model analysis (2017)
Journal Article
Bakker, E., Tian, K., Mutti, L., Demonacos, C., Schwartz, J., & Krstic-Demonacos, M. (2017). Insight into glucocorticoid receptor signalling through interactome model analysis. PLoS Computational Biology, 13(11), https://doi.org/10.1371/journal.pcbi.1005825

Glucocorticoid hormones (GCs) are used to treat a variety of diseases because of their potent anti-inflammatory effect and their ability to induce apoptosis in lymphoid malignancies through the glucocorticoid receptor (GR). Despite ongoing research,... Read More about Insight into glucocorticoid receptor signalling through interactome model analysis.

Immunotherapy advances for mesothelioma treatment (2017)
Journal Article

Introduction: Mesothelioma is a rare type of cancer that is strongly tied to asbestos exposure. Despite application of different modalities such as chemotherapy, radiotherapy and surgery, patient prognosis remains very poor and therapies are ineffect... Read More about Immunotherapy advances for mesothelioma treatment.

Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma (2017)
Journal Article
Guazzelli, A., Bakker, E., Tian, K., Demonacos, C., Krstic- Demonacos, M., & Mutti, L. (2017). Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma. Expert Opinion on Investigational Drugs, 26(8), 933-944. https://doi.org/10.1080/13543784.2017.1351545

Introduction: Malignant mesothelioma is a rare and lethal malignancy primarily affecting the pleura and peritoneum. Mesothelioma incidence is expected to increase worldwide and current treatments remain ineffective, leading to poor prognosis. Within... Read More about Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.

Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia (2017)
Journal Article

Glucocorticoids (GCs) and topoisomerase II inhibitors are used to treat acute lymphoblastic leukaemia (ALL) as they induce death in lymphoid cells through the glucocorticoid receptor (GR) and p53 respectively. Mechanisms underlying ALL cell death and... Read More about Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia.

Current and prospective pharmacotherapies for the treatment of pleural mesothelioma (2017)
Journal Article

Introduction: Mesothelioma is a rare asbestos-linked cancer with an expected incidence peak between 2015–2030. Therapies remain ineffective, thus developing and testing novel treatments is important for both oncologists and researchers.


Areas co... Read More about Current and prospective pharmacotherapies for the treatment of pleural mesothelioma.

Anti-CTLA-4 therapy for malignant mesothelioma (2017)
Journal Article
Guazzelli, A., Bakker, E., Krstic-Demonacos, M., Lisanti, M., Sotgia, F., & Mutti, L. (2017). Anti-CTLA-4 therapy for malignant mesothelioma. Immunotherapy, 9(3), 273-280. https://doi.org/10.2217/imt-2016-0123

Immunotherapy is an emerging therapeutic strategy with a promising clinical outcome in some solid tumors, particularly metastatic melanoma. One approach to immunotherapy is immune checkpoint inhibitors, such as blockage of CTLA-4 and PD-1/PD-L1. This... Read More about Anti-CTLA-4 therapy for malignant mesothelioma.

miR-663a regulates growth of colon cancer cells, after administration of antimicrobial peptides, by targeting CXCR4-p21 pathway (2017)
Journal Article
peptides, by targeting CXCR4-p21 pathway. BMC Cancer, 17, 33-43. https://doi.org/10.1186/s12885-016-3003-9

Abstract
Background: Antimicrobial peptides (AMPs) play important roles in the innate immune system of all life forms and
recently have been characterized as multifunctional peptides that have a variety of biological roles such as anticancer
agent... Read More about miR-663a regulates growth of colon cancer cells, after administration of antimicrobial peptides, by targeting CXCR4-p21 pathway.

Oxidative stress and breast cancer biomarkers : the case of the cytochrome P450 2E1 (2016)
Journal Article
Singh, S., Rajendran, R., Kuroda, K., Isogai, E., Krstic-Demonacos, M., & Demonacos, C. (2016). Oxidative stress and breast cancer biomarkers : the case of the cytochrome P450 2E1. Journal of Cancer Metastasis and Treatment, 2, 268-276. https://doi.org/10.20517/2394-4722.2016.42

Aim: The aim of the study is to investigate the impact of the cytochrome P450 2E1, which is the most efficient CYP450 family
member in generating reactive oxygen species (ROS), on cellular energy metabolism of breast cancer cells and therefore the... Read More about Oxidative stress and breast cancer biomarkers : the case of the cytochrome P450 2E1.

Repurposing atovaquone : targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells (2016)
Journal Article

Atovaquone is an FDA-approved anti-malarial drug, which first became clinically available in the year 2000. Currently, its main usage is for the treatment of pneumocystis pneumonia (PCP) and/or toxoplasmosis in immune-compromised patients. Atovaquone... Read More about Repurposing atovaquone : targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells.

Tremelimumab for the treatment of malignant mesothelioma (2015)
Journal Article
Guazzelli, A., Hussain, M., Krstic- Demonacos, M., & Mutti, L. (2015). Tremelimumab for the treatment of malignant mesothelioma. Expert Opinion on Biological Therapy, 15(12), 1819-1829. https://doi.org/10.1517/14712598.2015.1116515

Introduction: Tremelimumab demonstrated therapeutic activity in different malignancies, including malignant pleural mesothelioma (MPM); however, continued research could improve the therapeutic index of this agent.

Areas covered: This review descr... Read More about Tremelimumab for the treatment of malignant mesothelioma.

The expanded p53 interactome as a predictive model for cancer therapy (2015)
Journal Article
Hussain, M., Tian, K., Mutti, L., Krstic-Demonacos, M., & Schwartz, J. (2015). The expanded p53 interactome as a predictive model for cancer therapy. Genomics and computational biology, 1(1), e20. https://doi.org/10.18547/gcb.2015.vol1.iss1.e20

The tumour suppressor gene TP53 is implicated in
the majority of all human cancers, thus pivotal to
genomic integrity. Even though over 72,000 PubMed
publications are linked with the keyword p53 and this
number is continuously increasing, due to... Read More about The expanded p53 interactome as a predictive model for cancer therapy.

The role of microenvironment and immunity in drug response in leukemia (2015)
Journal Article

Leukemia is a cancer of the white blood cells, with over 54,000 new cases per year diagnosed worldwide and a 5-year survival rate below 60%. This highlights a need for research into the mechanisms behind its etiology and causes of therapy failure. Th... Read More about The role of microenvironment and immunity in drug response in leukemia.

Novel therapies for cancer treatment : designing high affinity and selectivity ligands against SIRT1 (2015)
Presentation / Conference
Al-Sudani, B., Krstic- Demonacos, M., & Ragazzon, P. (2015, June). Novel therapies for cancer treatment : designing high affinity and selectivity ligands against SIRT1. Poster presented at EuroMedLab Paris 2015, Paris, France

The word ‘sirtuin’ (SIR) stands for Silent Information Regulator. SIRT1 is the most studied mammalian sirtuin and predominantly localises to the nucleus. Many sirtuins targets are involved in cancer and in many types of cancers, SIRT1 is found to be... Read More about Novel therapies for cancer treatment : designing high affinity and selectivity ligands against SIRT1.

Antimicrobial peptide FF/CAP18 induces apoptotic cell death in HCT116 colon cancer cells via changes in the metabolic profile (2015)
Journal Article
Kuroda, K., Fukuda, T., Isogai, H., Okumura K, K., Krstic-Demonacos, M., & Isogai, E. (2015). Antimicrobial peptide FF/CAP18 induces apoptotic cell death in HCT116 colon cancer cells via changes in the metabolic profile. International Journal of Oncology, 46(4), 1516-1526. https://doi.org/10.3892/ijo.2015.2887

Metabolic reprogramming is one of the hallmarks of cancer and can be targeted by therapeutic agents. We previously reported that cathelicidin-related or modified antimicrobial peptides, such as FF/CAP18, have antiproliferative effects on the squamous... Read More about Antimicrobial peptide FF/CAP18 induces apoptotic cell death in HCT116 colon cancer cells via changes in the metabolic profile.

Applications of p53 interactome analysis to personalised drug discovery (2014)
Presentation / Conference
Hussain, M., Stutchbury, B., Tian, K., Atalay, R., Schwartz, J., & Krstic-Demonacos, M. (2014, April). Applications of p53 interactome analysis to personalised drug discovery. Presented at Conference: International Work-Conference on Bioinformatics and Biomedical Engineering (IWBBIO 2014), Universidad de Granada, Granada, Spain

The stress responsive transcription factor p53 is a powerful tumor suppressor implicated in over 50 % of all human cancers. The complexity and nonlinear dynamics of p53 network coupled with extensive literature is challenging. Sys-tems biology method... Read More about Applications of p53 interactome analysis to personalised drug discovery.

The role of the human endonuclease VIII-like 1 and 3 in the repair of DNA replication blocking lesions
Thesis
Martin, P. (in press). The role of the human endonuclease VIII-like 1 and 3 in the repair of DNA replication blocking lesions. (Thesis). University of Salford

The endonuclease VIII family of DNA glycosylases initiate repair of oxidative DNA base damage through BER and have been shown to resolve DNA inter-strand crosslinks (ICLs), arising from exogenous agents. Human NEIL1 (hNEIL1) activity on psoralen gene... Read More about The role of the human endonuclease VIII-like 1 and 3 in the repair of DNA replication blocking lesions.

Molecular pathways controlling DNA damage response
Thesis
Alhebshi, H. (in press). Molecular pathways controlling DNA damage response. (Thesis). University of Salford

P53 is inactivated in around 50 % of human neoplasms and more than 26,000 somatic mutations of the p53 have reported in human cancers. P53 network is activated after cells are exposed to the DNA damage and depending on diverse conditions and type of... Read More about Molecular pathways controlling DNA damage response.

Regulation of autophagy, endoplasmic reticulum and unfolded protein response by glucocorticoids in physiology and disease
Thesis
Sudsaward, S. (in press). Regulation of autophagy, endoplasmic reticulum and unfolded protein response by glucocorticoids in physiology and disease. (Thesis). University of Salford

Acute lymphoblastic leukemia (ALL) is the most frequent cancer in children, and although highly treatable, challenges remain due to significant side effects of therapy and the poor outcome for some patients. Synthetic glucocorticoid, Dexamethasone (D... Read More about Regulation of autophagy, endoplasmic reticulum and unfolded protein response by glucocorticoids in physiology and disease.